EMVision Receives $2.12m R&D Tax Rebate
Filed with ASX · · 2 pages · English
Summary by 6ix AI
EMVision Medical Devices Ltd. has announced the receipt of a cash rebate from its R&D tax incentive claim for the financial year ending in the middle of the year. Some R&D costs from the previous financial year have been capitalised and may qualify for future rebates.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- Algorithms Deliver Excellent Results In EMView Study
- EMV Prepares for Trial Following Positive FDA Engagement
- Appendix 4E & Annual Report to 30 June 2024
- First Responder Device Unveiled
- Stage 3 Recuitment Achieved & FDA Engagement Underway
Later from EMvision Medical Devices
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Releases its FY25 Half Yearly Report
- S&P DJI Announces March 2025 Quarterly Rebalance
- First Responder Scanner in Successful Aeromedical Testing
- Emu Pivotal Validation Trial Commences
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices